Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for overseas listing applications for 16 companies, focusing on compliance with various regulations and governance issues [1][2][3]. Group 1: Supplementary Material Requirements - Companies such as ZHONGAN XINKE and HANGZHOU JIAYIN are required to clarify their compliance with human genetic resource management regulations [1][10]. - For JIAZHI TECHNOLOGY, the company must explain the approval status of its actual controller's establishment and control of the issuer, and the implications of any changes in control [1][12]. - QIAN DAMA needs to address the share capital situation, including the specifics of share issuance and the exit of significant shareholders [2][15]. - JINGWANG ELECTRONICS is required to provide details on the compliance of its overseas subsidiaries with foreign investment and foreign exchange registration procedures [2][20]. Group 2: Governance and Compliance Issues - BEITONG DATA must clarify the compliance of its shareholding structure and return investment processes, including the pricing and legality of past transactions [3][4]. - KEDA INTELLIGENT is asked to specify the proportion of raised funds intended for domestic versus overseas use [4][40]. - PUQI PHARMACEUTICAL needs to explain the reasons behind shareholding arrangements and the legality of past shareholding changes [4][41]. Group 3: Specific Company Requirements - WOKER FEIFAN must clarify the fairness of historical share transfer prices and the rationale behind discrepancies in share issuance prices [5][18]. - HUA YAN ROBOTICS is required to confirm whether its business scope aligns with foreign investment access policies [6][21]. - FOURIER SEMICONDUCTOR must provide details on its compliance with foreign investment regulations and the status of its overseas subsidiaries [6][26].

证券代码：688192 证券简称：迪哲医药 公告编号：2026-012 此前，舒沃哲®二/后线单药治疗 EGFR exon20ins NSCLC 已在中、美两国获 批，成为该领域唯一中美双获批、国内外权威指南最高等级一致推荐且医保可及 1 的口服靶向药物，也是目前中国首个独立研发并在美获批的同类首创新药。基于 既往研究数据，舒沃哲®单药一线治疗 EGFR exon20ins NSCLC 已获中、美两国 授予的"突破性疗法认定"（BTD）。基于"悟空 28"的结果，公司计划近期 与药品监管部门沟通新药上市申请。 迪哲（江苏）医药股份有限公司 自愿披露关于舒沃哲®单药一线治疗 EGFR exon20ins 非小细胞肺癌国际多中心 III 期临床试验 获阳性顶线结果的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迪哲（江苏）医药股份有限公司（以下简称"公司"）宣布，其自主研发的 产品舒沃哲®（ZEGFROVY®，通用名：舒沃替尼片）单药一线治疗表皮生长因 子受体（EGFR）20 号外显子插入突变（exon20ins）晚期非 ...

Group 1 - The core viewpoint of the news is that Dize Pharmaceutical (688192.SH) is currently experiencing a decline in stock price, with a closing price of 49.19 yuan and a drop of 3.00%, resulting in a total market value of 22.855 billion yuan [1] - Dize Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 10, 2021, issuing 40.001 million shares at a price of 52.58 yuan per share [1] - The total funds raised from the initial public offering (IPO) amounted to 2.103 billion yuan, with a net amount of 1.987 billion yuan after deducting issuance costs, exceeding the original plan by 203 million yuan [1] - The company planned to use the raised funds of 1.783 billion yuan for new drug research and development projects and to supplement working capital [1] - The lead underwriter for the IPO was CITIC Securities Co., Ltd., with representatives Ding Yuan and Peng Liu, and the co-underwriter was Huatai United Securities Co., Ltd. [1] Group 2 - According to the verification report issued by Lixin Accounting Firm, the latest issuance involved 14 recipients at a price of 43.00 yuan per share, raising a total of approximately 1.799 billion yuan [2] - After deducting non-tax issuance costs of approximately 22.44 million yuan, the net amount raised was approximately 1.773 billion yuan [2] - Dize Pharmaceutical has raised a total of approximately 3.899 billion yuan from two fundraising rounds [3]

证券代码：688192 证券简称：迪哲医药 公告编号：2026-011 迪哲（江苏）医药股份有限公司 关于提前归还临时补充流动资金的闲置募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至 2026 年 3 月 6 日，公司已提前归还临时补充流动资金的闲置募 集资金人民币 10,336.33 万元。 一、募集资金临时补充流动资金情况 迪哲（江苏）医药股份有限公司（以下简称"公司"）于2025年4月29日召开 了第二届董事会第十三次会议、第二届监事会第十一次会议，审议通过了《关于 使用部分闲置募集资金临时补充流动资金的议案》，同意公司根据募集资金投资 项目的资金使用计划及项目的建设进度，在确保不影响募集资金投资项目建设进 度的前提下，使用总额不超过60,000万元（含本数）的部分闲置募集资金临时补 充流动资金，并仅用于与主营业务相关的生产经营使用，使用期限自董事会审议 通过之日起不超过12个月，到期归还至募集资金专用账户。具体内容详见公司于 2025年4月30日在上海证券交易所（www.sse.c ...

Core Viewpoint - Dige Pharmaceutical reported a significant increase in revenue for the year 2025, achieving a total operating income of 801.14 million yuan, which represents a year-on-year growth of 122.60% [2] Group 1 - The total operating income for 2025 reached 80113.56 million yuan [2] - The year-on-year growth rate of 122.60% indicates a strong performance compared to the previous year [2]

Group 1 - The core announcement is that Dize Pharmaceutical has changed its continuous supervision sponsor representative from Xu Chao to Mr. Blueprint, who will work alongside Ding Mingming for the company's IPO and 2023 annual private placement supervision, effective until December 31, 2027 [2]

Core Viewpoint - Dizh Pharmaceutical (688192) reported a significant increase in revenue for the fiscal year 2025, achieving approximately 800 million yuan, which represents a year-on-year growth of 122.6% while also reducing net losses to 763 million yuan [1] Group 1: Financial Performance - The company achieved a revenue of about 800 million yuan, marking a year-on-year increase of 122.6% [1] - The net profit attributable to shareholders was reported at -763 million yuan, indicating a reduction in losses compared to the previous year [1] Group 2: R&D and Product Development - Continuous investment in research and development is identified as a key factor for the company's high-quality growth [1] - The reporting period marks the first accounting year for two of the company's products included in the national medical insurance, leading to rapid sales growth [1] - Sales revenue from these products reached a total of 800 million yuan, with product launches expected to significantly impact the company's financial performance [1]

Core Viewpoint - The company reported significant revenue growth for 2025, with total revenue reaching 801 million yuan, a year-on-year increase of 122.6%, while the net loss decreased to 763 million yuan from 846 million yuan in the previous year [1] Financial Performance - Total revenue for 2025 was 801 million yuan, reflecting a 122.6% increase compared to the previous year [1] - The net loss attributable to the parent company was 763 million yuan, an improvement from a loss of 846 million yuan in the prior year [1] Product Development and Market Impact - Two products,舒沃哲® (generic name:舒沃替尼片) and高瑞哲® (generic name:戈利昔替尼胶囊), were included in the national medical insurance drug list for the first time, enhancing patient accessibility [1] - The company has intensified product promotion efforts and is actively expanding market share, positively impacting its operations [1]

Core Viewpoint - DIZHE Pharmaceutical (688192.SH) reported a significant financial performance for the fiscal year 2025, with total revenue of 800 million yuan, but also recorded substantial losses in operating profit and net profit [1] Financial Performance - The company achieved total operating revenue of 800 million yuan for the year 2025 [1] - Operating profit was reported at -766 million yuan, indicating a loss [1] - The net profit attributable to the parent company was -763 million yuan [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, was -842 million yuan [1] Product Development and Market Impact - Continuous investment in research and development is crucial for the company's high-quality growth, particularly in the field of innovative drugs [1] - The reporting period marks the first accounting year for two of the company's products included in the national medical insurance, leading to rapid sales growth [1] - The combined sales revenue from these products reached 800 million yuan, highlighting the impact of product launches on the company's financial status [1]

证券代码：688192 证券简称：迪哲医药 公告编号：2026-010 迪哲（江苏）医药股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迪哲（江苏）医药股份有限公司（以下简称"公司"）于近日收到持续督导 保荐机构华泰联合证券有限责任公司（以下简称"华泰联合"）出具的《关于更 换迪哲（江苏）医药股份有限公司首次公开发行股票及 2023 年度向特定对象发 行 A 股股票持续督导保荐代表人的函》。 公司首次公开发行股票并于 2021 年 12 月 10 日在上海证券交易所科创板上 市，聘请了中信证券股份有限公司（以下简称"中信证券"）担任首次公开发行 股票并在科创板上市的保荐机构，中信证券指派丁元女士、彭浏用先生担任保荐 代表人，持续督导期至 2024 年 12 月 31 日止。 公司于 2023 年 3 月 24 日召开第一届董事会第十六次会议、于 2023 年 4 月 14 日召开 2022 年年度股东大会，审议通过了《2023 年度向特定对象发行 A 股 股票预案》等相关议案。 ...